Greg Zante, Chief Financial Officer at Viking Therapeutics, Inc. (VKTX), sold 31,772 shares at $57.71 ($1.8M) on 2024-07-30, disclosed to the SEC on 2024-07-31.
Open-market sale of $1.8M VKTX by Chief Financial Officer. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $56.96 | 12,662 | $721K | 39.7% |
| 2 | $56.96 | 12,662 | $721K | 39.7% |
| 3 | $57.71 | 2,974 | $172K | 9.5% |
| 4 | $57.71 | 2,974 | $172K | 9.5% |
| 5 | $58.71 | 500 | $29K | 1.6% |
| Total | $57.13 avg | 31,772 |
| $1.8M |
| 100% |
| Filing → |
| VKTX | SELL | 2025-10-28 | $216K | — | Filing → |
| VKTX | SELL | 2025-07-03 | $237K | — | Filing → |
| VKTX | SELL | 2025-01-06 | $4.1M | — | Filing → |